Comparison of polyethylene glycol-electrolyte solution vs polyethylene glycol-3350 for the treatment of fecal impaction in pediatric patients

Erin E. Boles, Cameryn L. Gaines, Emma Tillman

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

OBJECTIVES: The objective of this study was to evaluate the safety and efficacy of polyethylene glycolelectrolyte solution vs polyethylene glycol-3350 for the treatment of fecal impaction in pediatric patients. METHODS: A retrospective, observational, institutional review board–approved study was conducted over a 1-year time period. Patients were included in the study if they were admitted to the hospital with a diagnosis of fecal impaction or constipation and were treated with either polyethylene glycol-electrolyte solution (PEG-ES) or polyethylene glycol-3350 (PEG-3350). Patients were excluded if they were discharged prior to resolution of treatment and/or did not receive PEG-ES or PEG-3350. RESULTS: Fifty-one patients (ranging in age from 1 month to 15 years) were evaluated: 23 patients received PEG-ES and 28 patients received PEG-3350. Sex, race, age, and weight were not statistically different between the 2 groups. Resolution of fecal impaction was not significantly different between PEG-ES vs PEG-3350 (87% and 86%, respectively; p = 0.87). There was only 1 reported side effect with PEG-3350, vs 11 reported side effects with PEG-ES (p < 0.01). CONCLUSIONS: Theses results suggest that PEG-3350 is as effective as PEG-ES for the treatment of fecal impaction in pediatric patients and is associated with fewer side effects.

Original languageEnglish (US)
Pages (from-to)210-216
Number of pages7
JournalJournal of Pediatric Pharmacology and Therapeutics
Volume20
Issue number3
DOIs
StatePublished - May 1 2015
Externally publishedYes

Fingerprint

Fecal Impaction
Electrolytes
Pediatrics
Therapeutics
Polyethylene
Constipation
polyethylene glycol 3350
Safety
Weights and Measures

Keywords

  • Constipation
  • Fecal impaction
  • Pediatrics
  • Polyethylene glycol-3350
  • Polyethylene glycol-electrolyte solution

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pharmacology (medical)

Cite this

@article{eea867ce20844adf98c04c3db03cd07d,
title = "Comparison of polyethylene glycol-electrolyte solution vs polyethylene glycol-3350 for the treatment of fecal impaction in pediatric patients",
abstract = "OBJECTIVES: The objective of this study was to evaluate the safety and efficacy of polyethylene glycolelectrolyte solution vs polyethylene glycol-3350 for the treatment of fecal impaction in pediatric patients. METHODS: A retrospective, observational, institutional review board–approved study was conducted over a 1-year time period. Patients were included in the study if they were admitted to the hospital with a diagnosis of fecal impaction or constipation and were treated with either polyethylene glycol-electrolyte solution (PEG-ES) or polyethylene glycol-3350 (PEG-3350). Patients were excluded if they were discharged prior to resolution of treatment and/or did not receive PEG-ES or PEG-3350. RESULTS: Fifty-one patients (ranging in age from 1 month to 15 years) were evaluated: 23 patients received PEG-ES and 28 patients received PEG-3350. Sex, race, age, and weight were not statistically different between the 2 groups. Resolution of fecal impaction was not significantly different between PEG-ES vs PEG-3350 (87{\%} and 86{\%}, respectively; p = 0.87). There was only 1 reported side effect with PEG-3350, vs 11 reported side effects with PEG-ES (p < 0.01). CONCLUSIONS: Theses results suggest that PEG-3350 is as effective as PEG-ES for the treatment of fecal impaction in pediatric patients and is associated with fewer side effects.",
keywords = "Constipation, Fecal impaction, Pediatrics, Polyethylene glycol-3350, Polyethylene glycol-electrolyte solution",
author = "Boles, {Erin E.} and Gaines, {Cameryn L.} and Emma Tillman",
year = "2015",
month = "5",
day = "1",
doi = "10.5863/1551-6776-20.3.210",
language = "English (US)",
volume = "20",
pages = "210--216",
journal = "Journal of Pediatric Pharmacology and Therapeutics",
issn = "1551-6776",
publisher = "Pediatric Pharmacology Advocacy Group, Inc.",
number = "3",

}

TY - JOUR

T1 - Comparison of polyethylene glycol-electrolyte solution vs polyethylene glycol-3350 for the treatment of fecal impaction in pediatric patients

AU - Boles, Erin E.

AU - Gaines, Cameryn L.

AU - Tillman, Emma

PY - 2015/5/1

Y1 - 2015/5/1

N2 - OBJECTIVES: The objective of this study was to evaluate the safety and efficacy of polyethylene glycolelectrolyte solution vs polyethylene glycol-3350 for the treatment of fecal impaction in pediatric patients. METHODS: A retrospective, observational, institutional review board–approved study was conducted over a 1-year time period. Patients were included in the study if they were admitted to the hospital with a diagnosis of fecal impaction or constipation and were treated with either polyethylene glycol-electrolyte solution (PEG-ES) or polyethylene glycol-3350 (PEG-3350). Patients were excluded if they were discharged prior to resolution of treatment and/or did not receive PEG-ES or PEG-3350. RESULTS: Fifty-one patients (ranging in age from 1 month to 15 years) were evaluated: 23 patients received PEG-ES and 28 patients received PEG-3350. Sex, race, age, and weight were not statistically different between the 2 groups. Resolution of fecal impaction was not significantly different between PEG-ES vs PEG-3350 (87% and 86%, respectively; p = 0.87). There was only 1 reported side effect with PEG-3350, vs 11 reported side effects with PEG-ES (p < 0.01). CONCLUSIONS: Theses results suggest that PEG-3350 is as effective as PEG-ES for the treatment of fecal impaction in pediatric patients and is associated with fewer side effects.

AB - OBJECTIVES: The objective of this study was to evaluate the safety and efficacy of polyethylene glycolelectrolyte solution vs polyethylene glycol-3350 for the treatment of fecal impaction in pediatric patients. METHODS: A retrospective, observational, institutional review board–approved study was conducted over a 1-year time period. Patients were included in the study if they were admitted to the hospital with a diagnosis of fecal impaction or constipation and were treated with either polyethylene glycol-electrolyte solution (PEG-ES) or polyethylene glycol-3350 (PEG-3350). Patients were excluded if they were discharged prior to resolution of treatment and/or did not receive PEG-ES or PEG-3350. RESULTS: Fifty-one patients (ranging in age from 1 month to 15 years) were evaluated: 23 patients received PEG-ES and 28 patients received PEG-3350. Sex, race, age, and weight were not statistically different between the 2 groups. Resolution of fecal impaction was not significantly different between PEG-ES vs PEG-3350 (87% and 86%, respectively; p = 0.87). There was only 1 reported side effect with PEG-3350, vs 11 reported side effects with PEG-ES (p < 0.01). CONCLUSIONS: Theses results suggest that PEG-3350 is as effective as PEG-ES for the treatment of fecal impaction in pediatric patients and is associated with fewer side effects.

KW - Constipation

KW - Fecal impaction

KW - Pediatrics

KW - Polyethylene glycol-3350

KW - Polyethylene glycol-electrolyte solution

UR - http://www.scopus.com/inward/record.url?scp=85015983909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015983909&partnerID=8YFLogxK

U2 - 10.5863/1551-6776-20.3.210

DO - 10.5863/1551-6776-20.3.210

M3 - Article

AN - SCOPUS:85015983909

VL - 20

SP - 210

EP - 216

JO - Journal of Pediatric Pharmacology and Therapeutics

JF - Journal of Pediatric Pharmacology and Therapeutics

SN - 1551-6776

IS - 3

ER -